EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Open Access · CC BY 4.0

A Phase 1, Open‐Label, Fixed‐Sequence, Drug–Drug Interaction Study of Zanubrutinib with Rifabutin in Healthy Volunteers

Bilal Tariq, Stephanie Conto, Aileen Cohen, Srikumar Sahasranaman, Ying C Ou

Clinical Pharmacology in Drug Development · 2023

DOI: 10.1002/cpdd.1250 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift Clinical Pharmacology in Drug Development, 2023. Verfasst von Bilal Tariq und 4 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Pharmacology, BeiGene USA, Inc., Fulton, Maryland, USA. Hauptthemen laut MEDLINE: Rifampin, Cytochrome P-450 CYP3A Inducers. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: BeiGene.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Zanubrutinib is a second‐generation Bruton tyrosine kinase inhibitor that is primarily metabolized by CYP3A enzymes. Previous drug–drug interaction (DDI) studies have demonstrated that co‐administration of zanubrutinib with rifampin, a strong CYP3A inducer, reduces zanubrutinib plasma concentrations, potentially impacting activity. The impact of the co‐administration of zanubrutinib with less potent CYP3A inducers is unclear. This phase 1, open‐label, fixed‐sequence DDI study evaluated the pharmacokinetics, safety, and tolerability of zanubrutinib when co‐administered with steady‐state rifabutin, a known CYP3A inducer less potent than rifampin, in 13 healthy male volunteers (NCT04470908). Co‐administration of zanubrutinib with rifabutin resulted in a less than 2‐fold reduction of zanubrutinib exposures. Overall, zanubrutinib was well tolerated. The results of this study provide useful information for the evaluation of the DDI between rifabutin and zanubrutinib. In conjunction with safety and efficacy data from other clinical studies, these results will be taken into consideration to determine the appropriate dose recommendation of zanubrutinib when co‐administered with CYP3A inducers.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RifampinCytochrome P-450 CYP3A InducersHumansMaleRifabutinHealthy VolunteersCytochrome P-450 CYP3ADrug InteractionsPiperidinesPyrazolesPyrimidines

Stichwörter der Autor:innen

BTKCYP3Adrug-drug interactionpharmacokineticrifabutinzanubrutinib

Substanzen

RifampinCytochrome P-450 CYP3A InducersRifabutinCytochrome P-450 CYP3AzanubrutinibPiperidinesPyrazolesPyrimidines

Autor:innen und Institutionen

  • Clinical Pharmacology, BeiGene USA, Inc., Fulton, Maryland, USA.
  • Clinical Operations, BeiGene USA, Inc., Cambridge, Massachusetts, USA.
  • BeiGene, Ltd. and BeiGene USA, Inc., San Mateo, California, USA.

Förderung

  • BeiGene

Zitieren

APA

Tariq, B., Conto, S., Cohen, A., Sahasranaman, S., & Ou, Y. C. (2023). A Phase 1, Open‐Label, Fixed‐Sequence, Drug–Drug Interaction Study of Zanubrutinib with Rifabutin in Healthy Volunteers. Clinical Pharmacology in Drug Development. https://doi.org/10.1002/cpdd.1250

Vancouver

Tariq B, Conto S, Cohen A, Sahasranaman S, Ou YC. A Phase 1, Open‐Label, Fixed‐Sequence, Drug–Drug Interaction Study of Zanubrutinib with Rifabutin in Healthy Volunteers. Clinical Pharmacology in Drug Development. 2023. doi:10.1002/cpdd.1250

BibTeX
@article{Tariq2023,
  author = {Tariq, Bilal and Conto, Stephanie and Cohen, Aileen and Sahasranaman, Srikumar and Ou, Ying C},
  title = {A Phase 1, Open‐Label, Fixed‐Sequence, Drug–Drug Interaction Study of Zanubrutinib with Rifabutin in Healthy Volunteers},
  journal = {Clinical Pharmacology in Drug Development},
  year = {2023},
  doi = {10.1002/cpdd.1250}
}
Kostenlos starten →